Literature DB >> 31104928

DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p.

Jie Mei1, Yifu Huang2, Leiyu Hao1, Yan Liu1, Ting Yan3, Tonglu Qiu1, Rui Xu1, Bujie Xu1, Zhuang Xiao1, Xiaozheng Jiang1, Kehan Hu1, Yichao Zhu4.   

Abstract

Ovarian cancer (OvCa) has the highest morbidity among all gynecologic cancers worldwide, and its distant metastasis is one of main causes for the poor prognosis of OvCa patients. Our previous studies have reported that DAAM1-involved signaling pathways play vital roles in metastasis of breast cancer. However, whether DAAM1 participates in OvCa migration and/or invasion is still unknown. The impact of DAAM1 on cell migration and invasion in OvCa was evaluated by wound healing assay and Boyden chamber assay. The specific miRNA targeting DAAM1 was predicted by bioinformatics methods and verified by dual-luciferase activity assay. The miR-208a-5p expression levels in OvCa tissues and the impacts of miR-208a-5p on cell migration and invasion were also assessed, respectively. High expression of DAAM1 was associated with distant metastasis in OvCa. Silence of DAAM1 by siRNA blocked the migration and invasion of OVCAR-3 cells. MiR-208a-5p directly targeted DAAM1 and was shown a decreased expression in metastatic OvCa tissues. Elevated expression of miR-208a-5p inhibited the migration and invasion of OVCAR-3 cell which can be rescued by DAAM1 overexpression. Our data suggest that miR-208-5p/DAAM1 axis participates in OvCa migration and invasion and may be a novel clinical target to limit OvCa metastasis.
Copyright © 2019 The Authors. Published by Elsevier GmbH.. All rights reserved.

Entities:  

Keywords:  DAAM1; Metastasis; Ovarian cancer; miR-208-5p

Mesh:

Substances:

Year:  2019        PMID: 31104928     DOI: 10.1016/j.prp.2019.152452

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

1.  LINC01006 facilitates cell proliferation, migration and invasion in prostate cancer through targeting miR-34a-5p to up-regulate DAAM1.

Authors:  Enhui Ma; Qianqian Wang; Jinhua Li; Xinqi Zhang; Zhenjia Guo; Xiaofeng Yang
Journal:  Cancer Cell Int       Date:  2020-10-19       Impact factor: 5.722

2.  Exploration of mRNAs and miRNA classifiers for various ATLL cancer subtypes using machine learning.

Authors:  Mohadeseh Zarei Ghobadi; Rahman Emamzadeh; Elaheh Afsaneh
Journal:  BMC Cancer       Date:  2022-04-21       Impact factor: 4.638

3.  Systematic summarization of the expression profiles and prognostic roles of the dishevelled gene family in hepatocellular carcinoma.

Authors:  Jie Mei; Xuejing Yang; Dandan Xia; Weijian Zhou; Dingyi Gu; Huiyu Wang; Chaoying Liu
Journal:  Mol Genet Genomic Med       Date:  2020-06-26       Impact factor: 2.183

4.  Network pharmacology-based analysis of the role of tacrolimus in liver transplantation.

Authors:  Lijian Chen; Yuming Peng; Chunyi Ji; Miaoxian Yuan; Qiang Yin
Journal:  Saudi J Biol Sci       Date:  2021-01-13       Impact factor: 4.219

5.  Daam1 Overexpression Promotes Gastric Cancer Progression and Regulates ERK and AKT Signaling Pathways.

Authors:  Yue Zhang; Xue Bai; Yi Zhang; Yan Li
Journal:  Onco Targets Ther       Date:  2021-08-27       Impact factor: 4.147

Review 6.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

7.  Dishevelled Associated Activator Of Morphogenesis (DAAM) Facilitates Invasion of Hepatocellular Carcinoma by Upregulating Hypoxia-Inducible Factor 1α (HIF-1α) Expression.

Authors:  Xiaoxu Fang; Dandan Zhang; Wei Zhao; Longfei Gao; Lanping Wang
Journal:  Med Sci Monit       Date:  2020-08-09

Review 8.  The Role of microRNAs in Epithelial Ovarian Cancer Metastasis.

Authors:  Vu Hong Loan Nguyen; Chenyang Yue; Kevin Y Du; Mohamed Salem; Jacob O'Brien; Chun Peng
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.